News & Press Releases
Xediton Pharmaceuticals Inc. announces a share purchase agreement with Valeo Pharma
Xediton Pharmaceuticals Inc., (“Xediton” or the “Purchaser”) a Canadian Specialty Pharmaceutical company, announced today that it has closed a share purchase agreement with Valeo Pharma Inc. (“Valeo” or the “Company”), in its proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”).
Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada
Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective products. Under the terms of the agreement, Xediton is responsible for the registration and commercialization of these products in Canada.